GeneNews is dedicated to providing innovative solutions for early cancer detection. Our mission is to identify, assess and make commercially available a comprehensive menu of diagnostics that provide physicians and patients with actionable information to improve health outcomes through the early diagnosis of disease. We work with healthcare providers to develop and implement processes that lead to higher screening rates and improved metrics around performance and care.
GeneNews Launches Blood-Based, Biomarker Test for Breast Cancer Risk Assessment
March 2017- GeneNews has launched a new risk stratification test for breast cancer, via its Virginia-based clinical reference lab, Innovative Diagnostics Laboratory ("IDL"). BreastSentry™ incorporates a blood-based biomarker test with a sophisticated algorithm to determine a woman's five-year and lifetime risk for developing breast cancer.
GeneNews aims to fix compliance gap in early cancer screening
GeneNews (TSX:GEN) is addressing the major issue in early cancer screening - patient reluctance with inconvenient and intrusive screening methods - with a suite of differentiated molecular diagnostic tests that rely on a convenient in-office blood draw to find cancers of the colon, lung, breast and prostate, early. “If patients will not undergo screening because of the test, it severely limits the usefulness,” chairman and CEO, James Howard-Tripp, says in an interview with BioTuesdays.“And because there is this compliance gap, healthcare providers are actively seeking ways to improve cancer screening and improve patient outcomes.” For example, he points out that the American Cancer Society has set an “80-by-18” goal for healthcare providers to have 80% of their qualified patient population screened for colorectal cancer by 2018. “Today, less than 59% of patients have met this goal,” he says, adding that colorectal cancer is highly preventable when detected early.